BIIB105

RNA / oligonucleotide

Also known as ION541

Stoppedregistry status

Evidence outlook

Development stopped: Phase 1/2 study terminated

The drug's registered studies are all terminated, withdrawn or suspended (NCT04494256: terminated); none completed, so no evidence signal is assigned. Check the registry record for the sponsor's stated reason.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)

Competitive landscape

Other ATXN2 (ataxin-2) drugs

SRP-1004. Compare all 2 ATXN2 (ataxin-2) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
BIIB105: this drugPhase 1/2RNA / oligonucleotideAtaxin-2 (ATXN2) mRNA, ATXN2 (ataxin-2)Weak signalFeatured results are safety only
SRP-1004
Phase 1(overall)
RNA / oligonucleotideATXN2 (ataxin-2)not yet gradedNo reviewed efficacy summary

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 May 2024Topline resultALSpire Phase 1/2 (NCT04494256) topline: no NfL reduction; BIIB105 development terminated
Biogen · Source ↗